Autoimmune thyroid disorders

Autoimmunity Reviews

Volumn 14, Issue 2, 2015, Pages 174-180

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Corrado, Alda ^a   Di Domenicantonio, Andrea ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Autoimmune thyroid diseases; Chemokines; CXCL10; Cytokines; Graves' disease; Hashimoto's thyroiditis

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; THYROID ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

AUTOIMMUNE DISEASE; AUTOIMMUNE THYROID DISEASE; CLINICAL FEATURE; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; FEEDBACK SYSTEM; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; IMMUNOPATHOGENESIS; LYMPHOCYTIC INFILTRATION; PREVALENCE; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SARCOIDOSIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TH1 CELL; THYROID CELL; THYROID DISEASE; THYROID GLAND; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROTOXICOSIS; AUTOIMMUNE THYROIDITIS; GENETIC PREDISPOSITION; IMMUNOLOGY; THYROID TUMOR;

CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS; THYROID NEOPLASMS; THYROIDITIS, AUTOIMMUNE;

EID: 84922526985     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.10.016     Document Type: Review

References (100)

1. Romagnani S. The Th1/Th2 paradigm and allergic disorders. Allergy 1998, 53:12-15.
2. Orgiazzi J. Thyroid autoimmunity. Presse Med 2012, 41:e611-e625.
3. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84:223-243.
4. Vanderpump M.P., Tunbridge W.M., French J.M., Appleton D., Bates D., Clark F., et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf) 1995, 43:55-68.
5. Pearce S.H., Leech N.J. Toward precise forecasting of autoimmune endocrinopathy. J Clin Endocrinol Metab 2004, 89:544-547.
6. McLeod D.S., Cooper D.S. The incidence and prevalence of thyroid autoimmunity. Endocrine 2012, 42:252-265.
7. McGrogan A., Seaman H.E., Wright J.W., de Vries C.S. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol (Oxf) 2008, 69:687-696.
8. Vanderpump M.P. The epidemiology of thyroid disease. Br Med Bull 2011, 99:39-51.
9. Tunbridge W.M., Evered D.C., Hall R., Appleton D., Brewis M., Clark F., et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977, 7:481-489.
10. Pedersen I.B., Laurberg P., Knudsen N., Jørgensen T., Perrild H., Ovesen L., et al. An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J Clin Endocrinol Metab 2007, 92:3122-3127.
11. Rizzo M., Rossi R.T., Bonaffini O., Scisca C., Altavilla G., Calbo L., et al. Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. Ann Endocrinol (Paris) 2010, 71:525-534.
12. Tomer Y., Davies T.F. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003, 24:694-717.
13. Hansen P.S1., Brix T.H., Iachine I., Kyvik K.O., Hegedüs L. The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins. Eur J Endocrinol 2006, 154:29-38.
14. Brix T.H., Hegedus L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol 2012, 76:457-464.
15. Simmonds M.J. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat Rev Endocrinol 2013, 9:277-287.
16. Tomer Y., Ban Y., Concepcion E., Barbesino G., Villanueva R., Greenberg D.A., et al. Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am J Hum Genet 2003, 73:736-747.
17. Smyth D., Cooper J.D., Collins J.E., Heward J.M., Franklyn J.A., Howson J.M., et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004, 53:3020-3023.
18. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
19. Gough S.C., Simmonds M.J. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics 2007, 8:453-465.
20. Lowe C.E., Cooper J.D., Brusko T., Walker N.M., Smyth D.J., Bailey R., et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007, 39:1074-1082.
21. Kochi Y., Yamada R., Suzuki A., Harley J.B., Shirasawa S., Sawada T., et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet 2005, 37:478-485.
22. Brand O.J., Barrett J.C., Simmonds M.J., Newby P.R., McCabe C.J., Bruce C.K., et al. Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum Mol Genet 2009, 18:1704-1713.
23. Chu X., Pan C.M., Zhao S.X., Liang J., Gao G.Q., Zhang X.M., et al. China Consortium for Genetics of Autoimmune Thyroid Disease. A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet 2011, 43:897-901.
24. Simmonds M.J. Evaluating the role of B Cells in autoimmune disease: more than just initiators of disease?. Advances in medicine and biology 2011, 151-176. Nova Science Publisher, Inc., New York. L.V. Berhardt (Ed.).
25. Castanet M., Polak M. Spectrum of human Foxe1/TTF2 mutations. Horm Res Paediatr 2010, 73:423-429.
26. Kawashima A., Tanigawa K., Akama T., Yoshihara A., Ishii N., Suzuki K. Innate immune activation and thyroid autoimmunity. J Clin Endocrinol Metab 2011, 96:3661-3671.
27. Dunkelmann S., Wolf R., Koch A., Kittner C., Groth P., Schuemichen C. Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging 2004, 31:1428-1434.
28. Agate L., Mariotti S., Elisei R., Mossa P., Pacini F., Molinaro E., et al. Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. J Clin Endocrinol Metab 2008, 93:2729-2736.
29. Laurberg P., Jørgensen T., Perrild H., Ovesen L., Knudsen N., Pedersen I.B., et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol 2006, 155:219-228.
30. Prummel M.F., Wiersinga W.M. Smoking and risk of Graves' disease. JAMA 1993, 269:479-482.
31. Bartalena L., Marcocci C., Tanda M.L., Manetti L., Dell'Unto E., Bartolomei M.P., et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998, 129:632-635.
32. Carlé A., Bülow Pedersen I., Knudsen N., Perrild H., Ovesen L., Banke Rasmussen L., et al. Smoking cessation is followed by a sharp but transient rise in the incidence of overt autoimmune hypothyroidism - a population-based, case-control study. Clin Endocrinol (Oxf) 2012, 77:764-772.
33. Drutel A., Archambeaud F., Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf) 2013, 78:155-164.
34. Mizokami T., Wu Li A., El-Kaissi S., Wall J.R. Stress and thyroid autoimmunity. Thyroid 2004, 14:1047-1055.
35. Lazarus J.H. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009, 23:723-733.
36. Martino E., Macchia E., Aghini-Lombardi F., Antonelli A., Lenziardi M., Concetti R., et al. Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis (AIIT)?. Clin Endocrinol (Oxf) 1986, 24:627-633.
37. Weetman A.P. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab 2009, 23:693-702.
38. Desailloud R., Hober D. Viruses and thyroiditis: an update. Virol J 2009, 6:5.
39. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Ghinoi A., Rotondi M., et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid 2006, 16:563-572.
40. Giordano T.P., Henderson L., Landgren O., Chiao E.Y., Kramer J.R., El-Serag H., et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007, 297:2010-2017.
41. Indolfi G., Stagi S., Bartolini E., Salti R., de Martino M., Azzari C., et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf) 2008, 68:117-121.
42. Antonelli A., Ferri C., Fallahi P., Giuggioli D., Nesti C., Longombardo G., et al. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004, 97:499-506.
43. Antonelli A., Ferri C., Fallahi P., Pampana A., Ferrari S.M., Barani L., et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007, 17:447-451.
44. Montella M., Crispo A., de Bellis G., Izzo F., Frigeri F., Ronga D., et al. HCV and cancer: a case-control study in a high-endemic area. Liver 2001, 21:335-341.
45. Ferri C., Antonelli A., Mascia M.T., Sebastiani M., Fallahi P., Ferrari D., et al. B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007, 7:114-120.
46. Antonelli A., Ferri C., Fallahi P., Nesti C., Zignego A.L., Maccheroni M. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol 2002, 20:693-696.
47. Gowans E.J. Distribution of markers of hepatitis C virus infection throughout the body. Semin Liver Dis 2000, 20:85-102.
48. Bartolomé J., Rodríguez-Iñigo E., Quadros P., Vidal S., Pascual-Miguelañez I., Rodríguez-Montes J.A., et al. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. J Med Virol 2008, 80:1588-1594.
49. Blackard J.T., Kong L., Huber A.K., Tomer Y. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid 2013, 23:863-870.
50. Menconi F., Hasham A., Tomer Y. Environmental triggers of thyroiditis: hepatitis C and interferon-α. J Endocrinol Invest 2011, 34:78-84.
51. Ferri C., Antonelli A., Mascia M.T., Sebastiani M., Fallahi P., Ferrari D., et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007, 39:13-21.
52. Villa E., Karampatou A., Cammà C., Di Leo A., Luongo M., Ferrari A., et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011, 140:818-829.
53. Fish E.N. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008, 8:737-744.
54. Armengol M.P., Juan M., Lucas-Martín A., Fernández-Figuera M.T., Jaraquemada D., Gallard T., et al. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol 2001, 159:861-873.
55. McIntosh R.S., Tandon N., Pickerill A.P., Davies R., Barnett D., Weetman A.P. IL-2 receptor-positive intrathyroidal lymphocytes in Graves' disease. Analysis of V alpha transcript microheterogeneity. J Immunol 1993, 151:3884-3893.
56. Pearce E.N., Farwell A.P., Braverman L.E. Thyroiditis. N Engl J Med 2003, 348:2646-2655.
57. Huber G., Staub J.J., Meier C., Mitrache C., Guglielmetti M., Huber P., et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002, 87:3221-3226.
58. McLachlan S.M., Rapoport B. Thyroid peroxidase as an autoantigen. Thyroid 2007, 17:939-948.
59. Costagliola S., Morgenthaler N.G., Hoermann R., Badenhoop K., Struck J., Freitag D., et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 1999, 84:90-97.
60. Madec A.M., Clavel S., Stefanutti A., Orgiazzi J. Blocking anti-thyrotropin receptor antibodies desensitize cultured human thyroid cells. Endocrinology 1988, 123:2062-2066.
61. Li Y., Kim J., Diana T., Klasen R., Olivo P.D., Kahaly G.J. A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity. Clin Exp Immunol 2013, 173:390-397.
62. Antonelli A., Rotondi M., Fallahi P., Ferrari S.M., Paolicchi A., Romagnani P., et al. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006, 34:32-38.
63. Antonelli A., Ferrari S.M., Giuggioli D., Ferrannini E., Ferri C., Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014, 13:272-280.
64. Antonelli A., Baj G., Marchetti P., Fallahi P., Surico N., Pupilli C., et al. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001, 50:985-991.
65. Antonelli A., Fallahi P., Delle Sedie A., Ferrari S.M., Maccheroni M., Bombardieri S., et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthritis. Clin Exp Rheumatol 2009, 27:22-27.
66. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Sebastiani M., Ferrari D., et al. High values of CXCL10 Serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008, 103:2488-2494.
67. Antonelli A., Ferri C., Fallahi P., Cazzato M., Ferrari S.M., Sebastiani M., et al. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol 2007, 156:431-437.
68. Antonelli A., Ferri C., Fallahi P., Colaci M., Giuggioli D., Ferrari S.M., et al. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol 2008, 35:1809-1811.
69. Ruffilli I., Ferrari S.M., Colaci M., Ferri C., Fallahi P., Antonelli A. IP-10 in autoimmune thyroiditis. Horm Metab Res 2014, 10.1055/s-0034-1382053.
70. Antonelli A., Rotondi M., Ferrari S.M., Fallahi P., Romagnani P., Franceschini S.S., et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006, 91:614-620.
71. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Santini E., Franceschini S.S., et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009, 94:1803-1809.
72. Antonelli A., Ferrari S.M., Frascerra S., Pupilli C., Mancusi C., Metelli M.R., et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab 2010, 95:413-420.
73. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Barani L., et al. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 2006, 64:189-195.
74. Antonelli A., Rotondi M., Fallahi P., Grosso M., Boni G., Ferrari S.M., et al. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 2007, 92:1485-1490.
75. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Serio M., Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006, 93:1226-1231.
76. Zhu W., Ye L., Shen L., Jiao Q., Huang F., Han R., et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 2014, 99:1999-2007.
77. Mysliwiec J., Palyga I., Kosciuszko M., Kowalska A., Gorska M. Circulating CXCL9 and CXCL10 as markers of activity of Graves' orbitopathy during treatment with corticosteroids and teleradiotherapy. Horm Metab Res 2012, 44:957-961.
78. Fallahi P., Ferrari S.M., Corrado A., Giuggioli D., Ferri C., Antonelli A. Targeting chemokine (C-X-C motif) receptor 3 in thyroid autoimmunity. Recent Patents Endocr Metab Immune Drug Discov 2014, 8:95-101.
79. Lee S.H., Lim S.Y., Choi J.H., Jung J.C., Oh S., Kook K.H., et al. Benzylideneacetophenone derivatives attenuate IFN-γ-induced IP-10/CXCL10 production in orbital fibroblasts of patients with thyroid-associated ophthalmopathy through STAT-1 inhibition. Exp Mol Med 2014, 46:100.
80. Dittmar M., Kahaly G.J. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003, 88:2983-2992.
81. Antonelli A., Tuomi T., Nannipieri M., Fallahi P., Nesti C., Okamoto H., et al. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002, 45:1298-1306.
82. Antonelli A., Fallahi P., Mosca M., Ferrari S.M., Ruffilli I., Corti A., et al. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism 2010, 59:896-900.
83. Antonelli A., Mosca M., Fallahi P., Neri R., Ferrari S.M., D'Ascanio A., et al. Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab 2010, 95:314-318.
84. Robazzi T.C., Adan L.F. Autoimmune thyroid disease in patients with rheumatic diseases. Rev Bras Reumatol 2012, 52:417-430.
85. Antonelli A., Fallahi P., Ferrari S.M., Mancusi C., Giuggioli D., Colaci M., et al. Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up. J Clin Endocrinol Metab 2013, 98:1198-1202.
86. Antonelli A., Fazzi P., Fallahi P., Ferrari S.M., Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest 2006, 130:526-532.
87. Antonelli A., Delle Sedie A., Fallahi P., Ferrari S.M., Maccheroni M., Ferrannini E., et al. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J Rheumatol 2006, 33:2026-2028.
88. Fallahi P., Ferrari S.M., Giuggioli D., Manfredi A., Mancusi C., Fabiani S., et al. Thyroid involvement in hepatitis C-associated mixed cryoglobulinemia. Hormones (Athens) 2014, 13:16-23.
89. Alfaris N., Curiel R., Tabbara S., Irwing M.S. Autoimmune thyroid disease and Sjögren syndrome. J Clin Rheumatol 2010, 16:146-147.
90. Namjou B., Kelly J.A., Kilpatrick J., Kaufman K.M., Nath S.K., Scofield R.H., et al. Linkage at 5q14.3-15 in multiplex systemic lupus erythematosus pedigrees stratified by autoimmune thyroid disease. Arthritis Rheum 2005, 52:3646-3650.
91. Molteni M., Barili M., Eisera N., Scrofani S., Mascagni B., Zulian C., et al. Anti-thyroid antibodies in Italian scleroderma patients: association of anti-thyroid peroxidase (anti-TPO) antibodies with HLA-DR15. Clin Exp Rheumatol 1997, 15:529-534.
92. Lee E.Y., Lee Z.H., Song Y.W. CXCL10 and autoimmune diseases. Autoimmun Rev 2009, 8:379-383.
93. Antonelli A., Ferrari S.M., Corrado A., Ferrannini E., Fallahi P. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev 2014, 25:57-65.
94. Boi F., Lai M.L., Marziani B., Minerba L., Faa G., Mariotti S. High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies. Eur J Endocrinol 2005, 153:637-642.
95. Fiore E., Rago T., Latrofa F., Provenzale M.A., Piaggi P., Delitala A., et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 2011, 18:429-437.
96. Boi F., Minerba L., Lai M.L., Marziani B., Figus B., Spanu F., et al. Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest 2013, 36:313-320.
97. Neri S., Boraschi P., Antonelli A., Falaschi F., Baschieri L. Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. Am J Ind Med 1996, 30:588-595.
98. Antonelli A., Bocci G., La Motta C., Ferrari S.M., Fallahi P., Fioravanti A., et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab 2011, 96:288-296.
99. Antonelli A., Fallahi P., Ferrari S.M., Carpi A., Berti P., Materazzi G., et al. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother 2008, 62:559-563.
100. Weetman A.P. Diseases associated with thyroid autoimmunity: explanations for the expanding spectrum. Clin Endocrinol (Oxf) 2011, 74:411-418.